GLP-1 受体激动剂联合门冬胰岛素30 对 2 型糖尿病患者控糖效果及体重的影响

李锦华; 张红; 李莹芳; 董志远; 刘云惠
June 2016
Progress in Modern Biomedicine;Jun2016, Vol. 16 Issue 18, p3500
Academic Journal
Objective: To investigate the effect of glucagon like peptide-1(GLP-1) receptor agonists combined with insulin aspart30 on the glucose control and weight of patients with type 2 diabetes mellitus. Methods: 116 patients with type 2 diabetes mellitus were selected as the research objects and were randomly divided into the research group(group A, n=58) and the control group(group B, n=58) by the random number table method. Group B were treated by insulin aspart 30 while group A were treated by insulin aspart 30 combined with liraglutide. Both of the two groups received continuous 24 weeks of treatment. The changes of glucose control indexes,lipid biochemical indexes and body mass index(BMI), etc. before and after the treatment were compared between the two groups. The differences in the first rates of blood glucose control, total rates of blood glucose control and the incidence of hypoglycemia were recorded. Results: â‘  6 months of treatment later, except that the differences in HDL-C levels in the two groups before and after the treatment were not statistically significant (P>0.05), glucose control indexes such as FBG, 2 hPG and HbA1c and lipid biochemical indexes such as TG, TC and LDL-C and BMI level were significantly lower than those before the treatment. The decreased range in group A was greater than that in groupB (P<0.05); â‘¡In group A, the first rate of blood glucose control (70.7%) and total rate of blood glucose control (100.0%) were significantly higher than those in groupB (37.9%, 93.1%) (P<0.05); â‘¢There were no serious adverse reactions and severe hypoglycemia events in the two groups, in which the incidence of mild hypoglycemia in group A [6.9%(4/58)] was significantly lower than that in group B [24.1%(14/58)] (P<0.05).Conclusion: To adopt insulin aspart 30 combined with GLP-1 receptor agonists in the clinical treatment of type 2 diabetes mellitus, the curative effect is definite and the effect of blood glucose control is good.It can effectively improve the blood lipid level, inhibit weight gain, and is good for improving the prognosis of patients.


Related Articles

  • Glp-3 is required for mitosis and meiosis in the Caenorhabditis elegans germ line. Kadyk, Lisa C.; Lambie, Eric J. // Genetics;Jan97, Vol. 145 Issue 1, p111 

    Focuses on the glp-3 gene, which is required for cell cycle progression in the Caenorhabditis elegans germ line. Identification and characterization of glp-3; Effects of glp-3 on the cell cycle progression in the germline; Nature of the cell cycle arrest in glp-3 mutants; Germline specificity...

  • Glucagon-Like Peptide 1 increases insulin sensitivity in depancreatized dogs. Sandhu, Harmanjit; Wiesenthal, Stephanie R.; MacDonald, Patrick E.; McCall, Richard H.; Tchipashvili, Vaja; Rashid, Shirya; Satkunarajah, Malathy; Irwin, David M.; Z. Qing Shi; Brubaker, Patricia L.; Wheeler, Michael B.; Vranic, Mladen; Efendic, Suad; Giacca, Adria // Diabetes;May99, Vol. 48 Issue 5, p1045 

    Determines the function of glucagon-like peptide 1 (GLP-1) on insulin sensitivity and secretion in depancreatized dogs. Differences in insulin-induced suppression of glucose production in GLP-1 and saline; Effect of GLP-1 on plasma glucose and insulin levels; Role of GLP-1 on insulin action...

  • Conservation of glp-1 Regulation and Function in Nematodes. Rudel, David; Kimble, Judith // Genetics;Feb2001, Vol. 157 Issue 2, p639 

    Examines the conservation of Caenorhabditis elegans glp-1 gene function and regulation in nematodes. Related studies on notch pathway controls; Description of Cr-glp-1 gene structure and transcripts; Analysis of conservation of GLP-1 architecture; Role of Cb-glp-1 in vulva development.

  • TYPE 1. Chanslor, J.; Perfetti, Riccardo // Diabetes Interview;Apr2004, Vol. 13 Issue 4, p16 

    Interviews researcher Lars Stene about glucagon-like peptide (GLP-1). Importance of GLP-1 for diabetes; Effect of GLP-1 on freshly isolated human islet creatures; Benefits of GLP-1 for human islet therapy.

  • 25 Years of Good Laboratory Practice. Immel, Barbara K. // BioPharm International;Jan2005, Vol. 18 Issue 1, p58 

    Discusses good laboratory practice (GLP) for nonclinical laboratory studies. Nonclinical laboratory studies that needed GLP; U.S. Food and Drug Administration's issuance of a chart that compares and contrasts the differences between GLP regulations; Difference between FDA GLP and good...

  • Glucagon-like Peptide-1.  // Encyclopedic Reference of Molecular Pharmacology;2004, p405 

    A definition of the term "glucagon-like peptide-1" (GLP1) is presented. Glucagon, GLP1 and GLP2 are three peptide hormones generated by a cleavage of a common precursor polypeptide. GLP1 stimulates insulin secretion from pancreatic B cells and inhibits feeding in fasted rats when injected into...

  • Defining equations for supergroup orbits in super Clifford modules. Bergvelt, M. J. // Journal of Mathematical Physics;Apr90, Vol. 31 Issue 4, p773 

    The defining equations for group orbits of a maximal subgroup of Glp|q in certain highest weight representations of the Lie super algebra glp|q are discussed.

  • Pancreatic GLP-1 receptor activation is sufficient for incretin control of glucose metabolism in mice. Lamont, Benjamin J.; Yazhou Li; Kwan, Edwin; Brown, Theodore J.; Gaisano, Herbert; Drucker, Daniel J. // Journal of Clinical Investigation;Jan2012, Vol. 122 Issue 1, p388 

    Glucagon-like peptide-1 (GLP-1) circulates at low levels and acts as an incretin hormone, potentiating glucose-dependent insulin secretion from islet β cells. GLP-1 also modulates gastric emptying and engages neural circuits in the portal region and CNS that contribute to GLP-1...

  • A Novel Long-Acting Glucagon-Like Peptide-1 Agonist with Improved Efficacy in Insulin Secretion and β-Cell Growth. Hee Young Kim; Jong-Ik Hwang; Mi Jin Moon; Jae Young Seong // Endocrinology & Metabolism;2014, Vol. 29 Issue 3, p320 

    Background: Glucagon-like peptide-1 (GLP-1) is an incretin hormone produced by cleavage of proglucagon in intestinal L-cells. In the pancreas, GLP-1 stimulates post-prandial insulin secretion, promotes insulin biosynthesis, and improves insulin sensitivity. Because of its insulinotropic...

  • Molecular modeling of the three-dimensional structure of GLP-1R and its interactions with several agonists. Fu Lin; Renxiao Wang // Journal of Molecular Modeling;Jan2009, Vol. 15 Issue 1, p53 

    Abstract  Glucagon-like peptide-1 receptor (GLP-1R) is a promising molecular target for developing drugs treating type 2 diabetes. We have predicted the complete three-dimensional structure of GLP-1R and the binding modes of several GLP-1R agonists, including GLP-1, Boc5, and Cpd1, through...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics